Omeros partnered with Novo Nordisk on zaltenibart development, while Intellia and Regeneron formed a collaboration on co-developing therapies. Separately, the FDA approved Omeros' Yartemlea for TA-TMA treatment.
1 report, 1 independent
Updated Jun 20
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Omeros partnered with Novo Nordisk on zaltenibart development, while Intellia and Regeneron formed a collaboration on co-developing therapies. Separately, the FDA approved Omeros' Yartemlea for TA-TMA treatment.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Novo Nordisk
Danish pharmaceutical company
-
Intellia Therapeutics
It is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system.
Nothing else this week.
-
Regeneron Pharmaceuticals
American pharmaceutical company
- FDA